22. What’s Next? The Phase 3 Clinical Trial

A much larger phase 3 clinical trial is now underway to confirm if lepodisiran’s dramatic Lp(a) reduction leads to real-world decreases in heart attacks and strokes.
Only with these results can the drug move toward regulatory approval and wider use.
For current trial information, visit
ClinicalTrials.gov.